UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
July
29, 2008
(Date
of
Earliest Event Reported)
Advaxis,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
00028489
|
02-0563870
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
Technology
Centre of New Jersey
675
Rt. 1, Suite B113
North
Brunswick, N.J. 08902
(Address
of principal executive offices)
(732)
545-1590 (Registrant’s
telephone number, including area code)
|
(Former
name or former address, if changed since last report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
On
July 29, 2008, Advaxis, Inc issued a press release regarding its Investigational
New Drug application for Lovaxin C.
A
copy of the press release is attached as Exhibit 99.1 to this Current Report
and
is incorporated herein by this reference.
Item
9.01 |
Financial
Statements and Exhibits
|
99.1 |
Advaxis,
Inc. press release, dated July 29,
2008
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, Registrant has
duly
caused this report to be signed on its behalf by the undersigned hereunto
duly
authorized.
Dated:
July 29, 2008
|
|
|
|
Advaxis,
Inc. |
|
|
|
|
By: |
/s/
Thomas A. Moore
|
|
Name:
Thomas A. Moore |
|
Title:
Chief Executive Officer |